Journal article
Systemic Immunomodulatory Treatments for Atopic Dermatitis
Abstract
Importance: There are multiple approved systemic treatments for atopic dermatitis. Lebrikizumab is a newly licensed biologic medication that has been compared to placebo in clinical trials but not to other systemic treatments.
Objective: To compare reported measures of efficacy and safety of lebrikizumab to other systemic treatments for atopic dermatitis in a living systematic review and network meta-analysis.
Authors
Drucker AM; Lam M; Prieto-Merino D; Malek R; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Mohan T
Journal
JAMA Dermatology, Vol. 160, No. 9, pp. 936–944
Publisher
American Medical Association (AMA)
Publication Date
September 1, 2024
DOI
10.1001/jamadermatol.2024.2192
ISSN
2168-6068